Moreover, BCG therapy can enhance PD‐L1, but not PD‐L2, expression on tumor cells and inflammatory T‐cells in tumoral and non‐tumoral tissue, which may explain the immune escape mechanism observed in BCG‐unresponsive cases (Figure 1).67, 68. This evidence concerns the gene CD274 and neoplasm.